A Prospective, Randomized, Open Label, Comparative Study of Resveratrol as an Add on Therapy in Systemic Hypertension

Selvam, G (2019) A Prospective, Randomized, Open Label, Comparative Study of Resveratrol as an Add on Therapy in Systemic Hypertension. Masters thesis, Madras Medical College, Chennai.

[img]
Preview
Text
200600119selvam.pdf

Download (9MB) | Preview
[img]
Preview
Text
200600119selvam_abstract.pdf

Download (10kB) | Preview

Abstract

OBJECTIVES: To evaluate the efficacy and tolerability of Resveratrol as an add on therapy to standard treatment in systemic hypertension. BACKGROUND: Hypertension is defined as abnormally high systolic and diastolic arterial pressure which remains consistently elevated throughout the day. Untreated hypertension can lead to coronary heart disease, stroke, nephropathy, retinopathy and other ophthalmic diseases. The majority of cases of hypertension are characterised as idiopathic. However, hypertension is associated with an unhealthy life style, including smoking, diet high in unsaturated fatty acids and salt, lack of exercise and obesity. Resveratrol is a naturally occuring flavonoid phytoalexin, which has antioxidant properties and is useful in the treatment of numerous diseases because of its cardioprotective, vasoprotective, antidiabetic and neuroprotective effect. Resveratrol is useful in controlling blood pressure when added to a standard anti hypertensive therapy by increasing the production of nitric oxide (NO), an endogenous and potent vasodilator. METHODS: A prospective, randomized, open labeled, comparative study was conducted on hypertension patients attending hypertension OPD of Rajiv Gandhi government general hospital. Patients who are newly diagnosed with stage 1 hypertension and with no co morbid disease were selected for the study. After screening, the study subjects (n=60) were allocated into 2 groups by simple randomization. Control group (n=30) patients received Tab. Amlodipine and study group (n=30) patients received Tab. Amlodipine and Cap. Resveratrol for 12 weeks and followed up after 4 weeks RESULTS: The primary outcome of the study was to measure the change in blood pressure. Reduction in systolic and diastolic blood pressure was significant at the end of 12 weeks (p < 0.05). No serious adverse events were reported in both groups. CONCLUSION: We conclude that Resveratrol supplementation improve the long term control over systolic and diastolic blood pressure and is well tolerated by the patients.

Item Type: Thesis (Masters)
Uncontrolled Keywords: Hypertension, Resveratrol, blood pressure, systolic, diastolic, Amlodipine.
Subjects: MEDICAL > Pharmacology
Depositing User: Subramani R
Date Deposited: 22 Aug 2019 14:43
Last Modified: 22 Aug 2019 14:43
URI: http://repository-tnmgrmu.ac.in/id/eprint/11106

Actions (login required)

View Item View Item